Project Grant R21HL172138
Award Date
1/1/25
Completion Date
11/30/26
Dollars Obligated
$116K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $114,938 to Brigham & Women's Hospital Inc. to investigate novel epigenetic mechanisms underlying calcific aortic valve disease (CAVD). The research aims to define the histone code of CAVD, determine downstream translational and post-translational signaling targets, and examine the role of epigenomic modifications on...
This $750,345 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The funding supports research to investigate the role of telomerase reverse transcriptase (TERT) in the osteogenic reprogramming of aortic valve interstitial cells, which can lead to calcific aortic valve disease. The project aims to elucidate the epigenetic and transcriptional changes directed by...
The National Heart Lung and Blood Institute (NHLBI) awarded a $810,650 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The funding will support the development and validation of an artificial intelligence (AI)-enabled algorithm to characterize fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and create an AI-powered risk score to predict...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to develop a novel bioprosthetic aortic valve using pulmonary visceral pleura (PVP) tissue. The total award amount is $742,323, with a performance period from December 2024 to November 2028. The research aims to evaluate the mechanical properties, hemodynamics, and long-term durability of the PVP valve, and compare its...
This $148,568 federal Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of inflammation and sex-specific differences in the progression of aortic valve stenosis (AVS). The key objectives are to: 1) delineate how secreted factors from valve cells impact macrophage phenotype and vice versa in a sex-dependent manner, and 2) elucidate sex-specific differences in AVS...
This $1,526,628 Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop artificial intelligence (AI) methods to predict biological cardiovascular age from echocardiography imaging data. The key objectives are to: (I) identify trajectories of accelerated versus delayed cardiovascular aging, (II) discern contributors to accelerated cardiovascular aging phenotypes, and (III)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $207,015 to the Children's Hospital Medical Center in Cincinnati, Ohio to study the effects of early retinoic acid signaling on cardiac valve development. The research aims to elucidate the developmental mechanisms driving normal heart valve formation, with the goal of gaining insights into the etiology of congenital valve...
This federal Project Grant award, valued at $181,392.00 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to optimize surgical procedures for congenital aortic valve disease. The Principal Investigator, Dr. Alexander D. Kaiser, will leverage a novel computational modeling framework to (1) simulate and optimize the leaflet geometry of bicuspidization repair and bioprinted valve replacement procedures, (2) validate the...
This federal Project Grant award of $2,010,071 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of Tie2 signaling in aortic valve remodeling. The award will fund a project to: 1) delineate the unique roles of Tie2 signaling in heart valve remodeling in vivo using genetically modified mouse models; 2) define the role of the Tie2-PI3K/AKT-FOXO1 signaling pathway during semilunar valve...
This $2,508,095 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at Yale University to investigate the role of aberrant cell-extracellular matrix interactions in the development of thoracic aortic disease. The project aims to elucidate the underlying molecular, cellular, and biomechanical mechanisms driving progressive deterioration of the aortic wall, leading to dilation,...